DxS Ltd

DxS is a personalised medicine company focused on providing genetic analysis services and technologies to enable the delivery of safe and effective medicines. We operate a full range of pharmacogenetic services using our proprietary Scorpions technology. The services provide support for drug development, diagnostic product development and pharmacodiagnostics

Contact Details: 48 Grafton Street Manchester M13 9XX United Kingdom Tel: 44 (0) 161 606 7201 Fax: 44 (0) 161 606 7313 Email: info@dxsgenotyping.com WWW: www.dxsgenotyping.com/

Loading...

Recent Publications by DxS Ltd:
Cancer biomarkers--a good start. DxS is a pharmacogenomics business operating at the interface between...	17th June, 2009	DxS Limited, Manchester, UK.	MLO Med Lab Obs. 2009 May;41(5):18, 20.
Design and use of scorpions fluorescent signaling molecules. A number of probe systems exist for the real-time detection of PCR...	20th September, 2008	DXS Ltd, Manchester, UK.	Methods Mol Biol. 2008;429:99-115. DOI Direct Link
DxS Ltd. DxS is a personalized medicine company that meets the needs of the...	17th June, 2008	DxS Ltd, 48 Grafton Street, Manchester, M13 9XX, UK.	Pharmacogenomics. 2008 Apr;9(4):463-7. DOI Direct Link
The impact of FDA guidance on pharmacogenomic data submissions on drug development. After a long wait, the US Food and Drug Administration (FDA) finally...	9th November, 2005		IDrugs. 2005 Aug;8(8):648-50.
DxS Ltd. DxS is a pharmacogenomics business operating at the interface between...	7th January, 2004	DxS Ltd, 48 Grafton St., Manchester, M13 9XX, UK.	Pharmacogenomics. 2003 Jan;4(1):97-101. DOI Direct Link
→View more DxS Ltd research publications.

Press Releases on DxS Ltd:
Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations	22nd June, 2009	Exosome Diagnostics, Inc.	NEW YORK, June 22 /PRNewswire/ -- Exosome Diagnostics, Inc. ("ExosomeDX") and DxS Ltd. ("DxS") today announced that they will collaborate on the development of blood-based
Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests	2nd June, 2008		PLEASANTON, California, June 2 /PRNewswire/ -- Roche and DxS Ltd. have signed an exclusive distribution agreement for the DxS TheraScreen K-RAS Mutation Test and TheraScreen EGFR 29 Mutation Test. The
DXS And Sangtec Molecular Diagnostics Announce Licensing Agreement Of	1st February, 2004	Dxs	DXS And Sangtec Molecular Diagnostics Announce Licensing Agreement Of Scorpions[Tm] Technology 18th February 2004 Manchester (UK) and Stockholm (Sweden): DxS Ltd, a genotyping services and

BioNews Results for DxS Ltd:
Qiagen Gains New Array Resources in SABiosciences Deal	GenomeWeb:  Nov 18 2009 12:10AM Matching: dxs
AACC Meeting Focuses on FDA Approval Process, Strategies to Bring Proteomics Dxs to Market	GenomeWeb:  Nov 11 2009 8:34PM Matching: dxs
Qiagen Snags SABiosciences for $90M to Boost Diagnostic Capabilities	Genetic Engineering News:  Nov 11 2009 12:27AM Matching: dxs
Qiagen bolsters assay tech with SABiosciences buy	Clinica:  Nov 10 2009 5:17PM Matching: dxs
A blossoming diagnostic duo	Drug Discovery News:  Nov 5 2009 10:59PM Matching: dxs
Promote your company here: BioNewsCast - Press Release Distribution	→View more DxS Ltd news.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 674 times since April 2007, the link to the organisation's website has been followed 161 times

Recent Search Terms used to find this page: Dxs Limited | dxs limited | DxS Ltd. | DxS Ltd | dxs Limited UK | DXS Ltd | DxS LTd | DxS ltd | dxs l | dxs l | .

Search for more companies in Manchester

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for DxS Ltd